Madeleine C. Brady
- Molecular Biology
- Cell Biology top 5%
- Oncology
- Health, Toxicology and Mutagenesis top 5%
- Biomedical Engineering
- Co-authors
- Nicole ClemannHorst SpielmannElke GenschowAldert H. PiersmaSusanne BremerF. PaillardHannele HuuskonenNigel A. Brown
- Topics
- Pluripotent Stem Cells Research (4 papers)Animal testing and alternatives (4 papers)Cancer-related Molecular Pathways (3 papers)
- Partner nations
- United KingdomFranceNetherlands
In The Last Decade
Madeleine C. Brady
13 papers receiving 922 citations
Peers
Comparison fields: 5 of 94
- Molecular Biology 574
- Cell Biology 254
- Oncology 198
- Health, Toxicology and Mutagenesis 167
- Biomedical Engineering 138
Countries citing papers authored by Madeleine C. Brady
This map shows the geographic impact of Madeleine C. Brady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madeleine C. Brady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madeleine C. Brady more than expected).
Fields of papers citing papers by Madeleine C. Brady
This network shows the impact of papers produced by Madeleine C. Brady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madeleine C. Brady. The network helps show where Madeleine C. Brady may publish in the future.
Co-authorship network of co-authors of Madeleine C. Brady
This figure shows the co-authorship network connecting the top 25 collaborators of Madeleine C. Brady. A scholar is included among the top collaborators of Madeleine C. Brady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madeleine C. Brady. Madeleine C. Brady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 37 | |
| 2 | 32 | |
| 3 | 6 | |
| 4 | 11 | |
| 5 | 278 | |
| 6 | AZD1152: A highly potent and specific aurora kinase inhibitor. | 6 |
| 7 | 91 | |
| 8 | 286 | |
| 9 | 30 | |
| 10 | S1-1 A European Centre for the Validation of Alternative Methods (ECVAM) validation of micromass, whole embryo and embryonic stem cell culture tests for embryotoxicity. (I. Recent Progress in In Vitro Techniques for Teratology Sutudies) | 0 |
| 11 | Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. | 97 |
| 12 | [Development of prediction models for three in vitro embryotoxicity tests which are evaluated in an ECVAM validation study] | 16 |
| 13 | 31 | |
| 14 | 34 |
About Madeleine C. Brady
Madeleine C. Brady is a scholar working on Small Animals, Genetics and Cell Biology, having authored 14 papers that have together received 955 indexed citations. Recurring topics across this work include Pluripotent Stem Cells Research (4 papers), Animal testing and alternatives (4 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cell Biology (254 citations), Health, Toxicology and Mutagenesis (167 citations) and Small Animals (77 citations). Madeleine C. Brady has collaborated with scholars based in United Kingdom, France and Netherlands. Frequent co-authors include Nicole Clemann, Horst Spielmann, Elke Genschow, Aldert H. Piersma, Susanne Bremer, F. Paillard, Hannele Huuskonen, Nigel A. Brown, A. Seiler and Klaus M. Becker. Their work appears in journals such as Nature Reviews Drug Discovery, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.